Cadrenal Therapeutics (CVKD) Competitors $16.17 +1.68 (+11.59%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CVKD vs. UNCY, PDSB, EPIX, ZIVO, VOR, ANVS, VTGN, OPTN, RPTX, and VHAQShould you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Unicycive Therapeutics (UNCY), PDS Biotechnology (PDSB), ESSA Pharma (EPIX), ZIVO Bioscience (ZIVO), Vor Biopharma (VOR), Annovis Bio (ANVS), Vistagen Therapeutics (VTGN), OptiNose (OPTN), Repare Therapeutics (RPTX), and Viveon Health Acquisition (VHAQ). These companies are all part of the "pharmaceutical products" industry. Cadrenal Therapeutics vs. Unicycive Therapeutics PDS Biotechnology ESSA Pharma ZIVO Bioscience Vor Biopharma Annovis Bio Vistagen Therapeutics OptiNose Repare Therapeutics Viveon Health Acquisition Unicycive Therapeutics (NASDAQ:UNCY) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, community ranking, risk, media sentiment and valuation. Which has stronger valuation & earnings, UNCY or CVKD? Cadrenal Therapeutics has lower revenue, but higher earnings than Unicycive Therapeutics. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnicycive Therapeutics$680K103.80-$30.54M-$0.97-0.70Cadrenal TherapeuticsN/AN/A-$8.36M-$6.68-2.42 Is UNCY or CVKD more profitable? Unicycive Therapeutics' return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Unicycive TherapeuticsN/A N/A -29.88% Cadrenal Therapeutics N/A -142.95%-118.40% Does the media favor UNCY or CVKD? In the previous week, Cadrenal Therapeutics had 1 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 1 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.56 beat Cadrenal Therapeutics' score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cadrenal Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, UNCY or CVKD? Unicycive Therapeutics has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Does the MarketBeat Community believe in UNCY or CVKD? Unicycive Therapeutics received 24 more outperform votes than Cadrenal Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cadrenal Therapeutics an outperform vote while only 75.00% of users gave Unicycive Therapeutics an outperform vote. CompanyUnderperformOutperformUnicycive TherapeuticsOutperform Votes3075.00% Underperform Votes1025.00% Cadrenal TherapeuticsOutperform Votes6100.00% Underperform VotesNo Votes Do analysts rate UNCY or CVKD? Unicycive Therapeutics presently has a consensus price target of $5.13, indicating a potential upside of 653.68%. Cadrenal Therapeutics has a consensus price target of $32.00, indicating a potential upside of 97.90%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Unicycive Therapeutics is more favorable than Cadrenal Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in UNCY or CVKD? 40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 24.1% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 48.6% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryUnicycive Therapeutics beats Cadrenal Therapeutics on 13 of the 17 factors compared between the two stocks. Ad InvestorPlaceWall Street Icon: “You must get on the right side of this thing”I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.This market shakeup is going to be much more intense. Get Cadrenal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVKD vs. The Competition Export to ExcelMetricCadrenal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.83M$6.57B$5.13B$9.08BDividend YieldN/A2.99%4.93%4.22%P/E Ratio-2.4210.5589.5817.18Price / SalesN/A195.351,115.01116.87Price / CashN/A57.1642.8237.86Price / Book1.835.104.804.78Net Income-$8.36M$151.51M$120.04M$225.60M7 Day Performance44.38%-2.12%-1.91%-1.23%1 Month Performance15.42%-3.10%11.48%3.36%1 Year PerformanceN/A11.54%30.59%16.59% Cadrenal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVKDCadrenal Therapeutics1.7091 of 5 stars$16.17+11.6%$32.00+97.9%N/A$26.83MN/A-2.424News CoverageGap UpHigh Trading VolumeUNCYUnicycive Therapeutics3.3831 of 5 stars$0.70-2.0%$5.13+632.1%+19.3%$72.66M$680,000.00-0.749PDSBPDS Biotechnology1.1339 of 5 stars$1.94+5.2%$11.67+502.9%-67.9%$72.39MN/A-1.5920Analyst ForecastNews CoverageEPIXESSA Pharma3.3486 of 5 stars$1.63-0.6%$9.50+482.8%-74.2%$72.32MN/A-2.6550Earnings ReportZIVOZIVO BioscienceN/A$20.00+0.8%N/A+1,339.4%$71M$30,000.00-4.0710News CoverageGap DownVORVor Biopharma2.5466 of 5 stars$1.02+2.9%$11.36+1,013.4%-59.7%$70.04MN/A-0.60140ANVSAnnovis Bio2.3121 of 5 stars$5.00-5.8%$32.17+543.3%-61.4%$68.99MN/A-1.193News CoverageVTGNVistagen Therapeutics0.9756 of 5 stars$2.47+1.6%N/A-51.0%$68.77M$1.06M-1.9640OPTNOptiNose4.0244 of 5 stars$0.45-3.6%$3.00+560.8%-64.1%$68.48M$70.99M-1.64190RPTXRepare Therapeutics3.4043 of 5 stars$1.60-9.6%$7.00+337.5%-79.8%$68.02M$51.13M-0.89180High Trading VolumeVHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$66.49MN/A0.002 Related Companies and Tools Related Companies UNCY Competitors PDSB Competitors EPIX Competitors ZIVO Competitors VOR Competitors ANVS Competitors VTGN Competitors OPTN Competitors RPTX Competitors VHAQ Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CVKD) was last updated on 12/22/2024 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CVKD Stock Alerts